Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
Martin H J WiesenCornelia BlaichMax TaubertVeronika JennissenThomas StreichertRoman PfisterGuido MichelsPublished in: European journal of clinical pharmacology (2018)
In the majority of patients, rivaroxaban plasma concentrations dropped below 30 ng/ml after 48 h of treatment discontinuation which is considered hemostatically safe before surgery with high bleeding risk. For accurate determination of low rivaroxaban concentrations, LC-MS/MS is the preferred choice.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- patients undergoing
- pulmonary embolism
- end stage renal disease
- ejection fraction
- minimally invasive
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- heart failure
- coronary artery bypass
- stem cells
- coronary artery disease
- molecularly imprinted
- combination therapy
- patient reported
- decision making
- replacement therapy